Publications by authors named "Michelle Finnegan"

Claim this Profile
C
Characterizing Prodrome (Premonitory Phase) in Migraine: Results From the PRODROME Trial Screening Period.
Todd J Schwedt, Richard B Lipton, Peter J Goadsby, Chia-Chun Chiang, Brad C Klein, Michelle Finnegan

Neurol Clin Pract· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial.
Richard B Lipton, Stephanie J Nahas, Patricia Pozo-Rosich, Tanya Bilchik, Peter McAllister, Michelle Finnegan

J Headache Pain· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
David W Dodick, Peter J Goadsby, Todd J Schwedt, Richard B Lipton, Chengcheng Liu, Michelle Finnegan

Lancet· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Patricia Pozo-Rosich, Jessica Ailani, Messoud Ashina, Peter J Goadsby, Richard B Lipton, Michelle Finnegan

Lancet· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
Brad C Klein, Rosa Miceli, Lawrence Severt, Peter McAllister, Laszlo Mechtler, Michelle Finnegan

Cephalalgia· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
Messoud Ashina, Stewart J Tepper, Uwe Reuter, Andrew M Blumenfeld, Susan Hutchinson, Michelle Finnegan

Headache· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total plasma homocysteine measurement: Evaluation of the Abbott immunoassay, comparison with the JEOL ion exchange chromatography and investigation of its clinical utility.
Kai Fung Kevin Suen, Graham R Lee, Michelle Finnegan, Kieran Halton, Ingrid Borovickova

Pract Lab Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain.
Richard B Lipton, David W Dodick, Peter J Goadsby, Rami Burstein, Aubrey M Adams, Michelle Finnegan

Neurology· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
Richard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, David W Dodick, Peter McAllister, Michelle Finnegan

JAMA Netw Open· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
Todd J Schwedt, Richard B Lipton, Jessica Ailani, Stephen D Silberstein, Cristina Tassorelli, Michelle Finnegan

Cephalalgia· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atogepant for the Preventive Treatment of Migraine.
Jessica Ailani, Richard B Lipton, Peter J Goadsby, Hua Guo, Rosa Miceli, Michelle Finnegan

N Engl J Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Andrew M Blumenfeld, Peter J Goadsby, David W Dodick, Susan Hutchinson, Chengcheng Liu, Michelle Finnegan

Headache· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
Peter J Goadsby, David W Dodick, Jessica Ailani, Joel M Trugman, Michelle Finnegan

Lancet Neurol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
Jessica Ailani, Richard B Lipton, Susan Hutchinson, Kerry Knievel, Kaifeng Lu, Michelle Finnegan

Headache· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
Peter J Goadsby, Stewart J Tepper, Paul B Watkins, Girma Ayele, Rosa Miceli, Michelle Finnegan

Cephalalgia· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ubrogepant for the Treatment of Migraine.
David W Dodick, Richard B Lipton, Jessica Ailani, Kaifeng Lu, Michelle Finnegan

N Engl J Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
Richard B Lipton, David W Dodick, Jessica Ailani, Kaifeng Lu, Michelle Finnegan

JAMA· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relative risk to the femoral nerve as a function of patient positioning: potential implications for trigger point dry needling of the iliacus muscle.
Andrew M Ball, Michelle Finnegan, Shane Koppenhaver, Will Freres, Jan Dommerholt

J Man Manip Ther· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myofascial pain and treatment: Editorial.
Jan Dommerholt, Todd Hooks, Li-Wei Chou, Michelle Finnegan

J Bodyw Mov Ther· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical overview of the current myofascial pain literature - February 2019.
Jan Dommerholt, Li-Wei Chou, Michelle Finnegan, Todd Hooks

J Bodyw Mov Ther· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical overview of the current myofascial pain literature - November 2018.
Jan Dommerholt, Todd Hooks, Li-Wei Chou, Michelle Finnegan

J Bodyw Mov Ther· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical overview of the current myofascial pain literature - July 2018.
Jan Dommerholt, Michelle Finnegan, Todd Hooks, Li-Wei Chou

J Bodyw Mov Ther· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical overview of the current myofascial pain literature - April 2018.
Jan Dommerholt, Li-Wei Chou, Michelle Finnegan, Todd Hooks

J Bodyw Mov Ther· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical overview of the current myofascial pain literature - January 2018.
Jan Dommerholt, Todd Hooks, Li-Wei Chou, Michelle Finnegan

J Bodyw Mov Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical overview of the current myofascial pain literature - October 2017.
Jan Dommerholt, Michelle Finnegan, Todd Hooks, Li-Wei Chou

J Bodyw Mov Ther· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis